Participated · Series B · Mar 2026

Vitestro is a Netherlands-headquartered medical-robotics company focused on automating diagnostic blood draws with its Aletta® Autonomous Robotic Phlebotomy Device™ (ARPD™). The CE-marked system combines multimodal imaging, advanced robotics, and artificial intelligence to locate veins, guide needle insertion, and collect blood with high precision and consistency. By standardizing venous access, the platform aims to alleviate staffing shortages, reduce variability, and improve patient experience in high-volume outpatient environments. Vitestro is currently deploying Aletta® in clinical and pre-commercial sites across Europe while pursuing a U.S. FDA De Novo clearance. Proceeds from its latest financing will fund next-generation product development, manufacturing scale-up, additional clinical studies, and the build-out of global commercial infrastructure.

Participated · Series A · Feb 2026

Prenosis develops AI-powered diagnostic and therapeutic tools that tailor care to each patient’s unique biological profile. Its core Immunix platform aggregates deep biological data to create diagnostics such as the Sepsis ImmunoScore, the first FDA-authorized AI test for sepsis. The company aims to commercialize ImmunoScore while continuing to expand its portfolio of biology-based diagnostics. Plans include deploying the platform in up to 40 academic medical centers to establish a precision-medicine clinical-trial network, enabling rapid recruitment of patients with specific biological signatures. Led by CEO Bobby Reddy, Jr., PhD, Prenosis positions itself at the intersection of data science, biology, and clinical practice to improve outcomes in critical conditions. The new capital will accelerate product rollout and broaden clinical integration efforts, supporting the company’s mission to personalize critical-care medicine.

Participated · Series A · Jan 2026

BIOMAKERS, headquartered in San Francisco, has built an integrated precision oncology ecosystem that combines large-scale molecular diagnostics, longitudinal real-world clinical data, and a deeply annotated tumor biobank. Its AI-native platform links genomic insights directly to patient samples and clinical outcomes, equipping life-science partners with intelligence to de-risk R&D, broaden trial access, and speed decision-making across the drug-development lifecycle. The company operates in more than 20 countries and runs clinical laboratories in Mexico, Brazil, and Argentina, giving it reach into diverse and under-sampled patient populations. BIOMAKERS’ tumor biobank exceeds 100,000 cases, and the firm maintains direct longitudinal connections to patients, physicians, and healthcare institutions. Having spent years assembling this infrastructure, it is now focused on scaling and monetizing the platform by deploying proprietary AI that structures and harmonizes electronic medical record data. This strategy positions BIOMAKERS as foundational infrastructure for global precision oncology R&D.

Participated · Series B · Jan 2026

Precede Biosciences is a precision diagnostics and data company that has built a proprietary, automated assay capable of extracting high-resolution, genome-wide transcriptional information from a single blood draw. The platform integrates this assay with advanced machine-learning analytics, enabling researchers and clinicians to profile target expression and pathway activity—critical biomarkers for drug-, radio- and immune-conjugates and other targeted therapies. By providing a multiplex, minimally invasive alternative to tissue biopsies, the company aims to accelerate drug development and ensure patients receive therapies precisely matched to their disease biology. Current commercial traction is described as “rapidly growing,” driven by partnerships with developers of next-generation precision medicines. The fresh financing brings Precede Bio’s total new capital to $83.5 million, giving the company resources to scale its platform and meet rising demand. An expanded investor base with deep diagnostics-commercialization expertise is expected to support health-system adoption and long-term growth.

Participated · Seed · Dec 2025

Cellens builds BioFeel, a mechanobiology and machine-learning platform that detects bladder cancer from urine samples by physically “feeling” cellular stiffness with atomic-force microscopy and converting those measurements into biophysical biomarkers. By relying on physics rather than solely on molecular markers, the test addresses tumor heterogeneity that limits current urine assays and eliminates many unnecessary, invasive cystoscopies. In a prospective study of nearly 100 patient samples, BioFeel correctly identified every recurrence case and markedly outperformed FDA-cleared molecular tests that typically reach only 60–65 % sensitivity. The technology originates from research at Tufts University and has been validated with Dartmouth Medical Center and the University of Washington Medical Center. With an estimated 83,190 new U.S. bladder-cancer cases in 2024 and 800,000 patients under surveillance, Cellens targets a large, costly monitoring market. The company plans to use its new capital to advance clinical validation, pursue regulatory clearance and scale commercialization. Cellens has raised $6.5 million in seed funding to date; no revenue metrics have been disclosed.